Evaluation of Calcium Electroporation for the Treatment of Cutaneous Metastases: A Double Blinded Randomised Controlled Phase II Trial

• Published in: Cancers Vol. 12; no. 1; p. 179
• Main Authors: Ágoston, Dóra, Baltás, Eszter, Ócsai, Henriette, Rátkai, Sándor, Lázár, Péter Gy, Korom, Irma, Varga, Erika, Németh, István Balázs, Dósa-Rácz Viharosné, Éva, Gehl, Julie, Oláh, Judit, Kemény, Lajos, Kis, Erika Gabriella
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 10-01-2020; MDPI
• Subjects: Adverse events; Anesthesia; Biopsy; Bleomycin; Breast cancer; Calcium; Chemotherapy; Clinical trials; Electroconvulsive therapy; Electroporation; Hyperpigmentation; Melanoma; Metastases; Metastasis; Patients; Skin cancer; Tumors; calcium electroporation; melanoma malignum; bleomycin-based electrochemotherapy; non-inferiority; randomization; biopsy; breast cancer; cutaneous metastases
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12010179

Calcium electroporation (Ca-EP) is a new anticancer treatment providing similar features to electrochemotherapy (ECT). The aim of our study is to compare the efficacy of Ca-EP with bleomycin-based ECT. This double-blinded randomized controlled phase II study was conducted at the Medical University of Szeged, Hungary. During this once only treatment up to ten measurable cutaneous metastases per patient were separately block randomized for intratumoral delivery of either calcium or bleomycin, which was followed by reversible electroporation. Tumour response was evaluated clinically and histologically six months after treatment. (ClinicalTrials.gov: NCT03628417, closed). Seven patients with 44 metastases (34 from malignant melanoma, 10 from breast cancer) were included in the study. Eleven metastases were taken for biopsies, and 33 metastases were randomised and treated once. The objective response rates were 33% (6/18) for Ca-EP and 53% (8/15) for bleomycin-based ECT, with 22% (4/18) and 40% (6/15) complete response rates, respectively. The CR was confirmed histologically in both arms. Serious adverse events were not registered. Ulceration and hyperpigmentation, both CTCA criteria grade I side effects, were observed more frequently after bleomycin-based ECT than for Ca-EP. Ca-EP was non-inferior to ECT, therefore, it should be considered as a feasible, effective and safe treatment option.